Two years after buying CinCor Pharma for $1.3 billion, AstraZeneca has reported that the main asset in the deal, for uncontrolled or treatment-resistant hypertension, has cleared a phase 3 trial.
The new method is called renal denervation, or RDN. It uses sound energy to target nerves linked to the main blood vessels ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback